NS-0100

AssetAlso called NS-0100-01, Low Metformin, Mid Metformin, High Metformin

Synergistic combination of leucine and metformin activating sirtuin and AMPK pathways to improve glycemic control.

Stage
Phase 2, no development reported
Modality
Small molecule
Target
Not known
1
Indication
2
Trials
1
Developer

No development reported since January 2016. Last activity: Trial NCT02435277 completed. clinicaltrials.gov

Indications

1

In the full profile

  • Target and mechanism1
  • Owner and partners1
  • Trials2
  • Evidence for its targets1
  • Competitors12
  • Aging relevance2
  • Signals5

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets